Recursion is Granted FDA Fast Track Designation for REC-2282 for the Potential Treatment of NF2-Mutated Meningiomas

October 7, 2021
Written By:
No items found.
Read the post ›
Proud founding member of BioHive, the fastest growing life sciences community in the nation

Get In Touch

41 S Rio Grande Street
Salt Lake City, UT 84101
phone: (385) 269-0203
fax: (801) 821-2872
info@recursion.com
Investor Relations

Connect

LinkedIn
Twitter
Youtube